Markets

Insider Trading

Hedge Funds

Retirement

Opinion

10 Firms Dominate Monday Upsurge

Ten companies—predominantly in the healthcare sector—kicked off Monday’s trading with notable gains amid a series of business updates, earnings, and acquisition deals that have fueled investor confidence.

Their gains outperformed mixed trading on Wall Street, with the Dow Jones and S&P’s main index the only gainers, up 0.86 percent and 0.16 percent, respectively. Meanwhile, the Nasdaq Composite dropped by 0.38 percent.

In this article, we will take a look at what buoyed the companies’ share prices.

To come up with Monday’s top gainers, we considered only the stocks with at least $2 billion in market capitalization and $5 million in daily trading volume.

A woman reading and analyzing stock market data. Photo by Artem Podrez on Pexels

10. Cleveland-Cliffs Inc. (NYSE:CLF)

Shares of an American steel manufacturer Cleveland-Cliffs (CLF) kicked off the trading week on a positive note, rallying by 5.96 percent to close at $10.49 apiece with investor sentiment buoyed by reports that it was looking to acquire United States Steel Corp. (X).

According to news, Cleveland-Cliffs (CLF) is currently in talks with Nucor Corp. (NUE) to jointly acquire US Steel (X) at over $30 per share. It would then sell US Steel’s Big River Steel subsidiary to Nucor.

The proposed acquisition came after President Joe Biden blocked a deal for Japan-based Nippon Steel to acquire US Steel for $14 billion.

According to Biden, steel producers, and the American steelworkers “are the backbone of our nation.”

“A strong domestically owned and operated steel industry represents an essential national security priority and is critical for resilient supply chains. … Without domestic steel production and domestic steelworkers, our nation is less strong and less secure,” he noted.

9. United States Steel Corp. (NYSE:X)

Shares of US Steel (X) rose for a second day on Monday as investors cheered news that two American companies have joined forces to acquire the former.

Over the weekend, reports said that Cleveland-Cliffs (CLF) was in talks with its rival Nucor Corp. (NUE) to jointly acquire US Steel (X) at more than $30 per share.

The proposed acquisition came after President Joe Biden blocked a deal for Japan-based Nippon Steel to acquire US Steel for $14 billion.

Biden blocked Nippon’s proposed acquisition of US Steel, saying the steel producers and the American steelworkers “are the backbone of our nation.” However, the administration announced that it delayed an order for Nippon to totally abandon the acquisition plan until June, fueling hopes that a deal could still push through.

Cleveland-Cliffs, however, remained mum on the reports.

8. Frontline Plc (NYSE:FRO)

Frontline (FRO) saw its stock prices grow by 6.21 percent to finish at $18.3 apiece as investors took heart from outgoing president Joe Biden’s official imposition of tariffs against Russia’s oil and gas sectors and its “shadow fleet.”

According to Biden, the taxes were sanctions slapped on Russia in a bid to reach a deal for peace in Ukraine.

Cyprus-based Frontline (FRO), currently the fourth largest oil tanker shipping firm globally, stands to benefit from the imposition of tariffs on Russian firms on expectations that oil buyers will look elsewhere for supply, including areas that it services.

Other oil-producing countries such as the Middle East and Africa may step in to fill the gap left by Russian exports.

7. CVS Health Corp. (NYSE:CVS)

Shares of CVS Health (CVS) rose by 7.31 percent on Monday to close at $51.52 apiece as investors snapped up stocks in the company ahead of a quarterly dividend distribution.

Earlier this month, CVS Health said that its board of directors gave the green light for a quarterly dividend of 66 cents for each of the corporation’s common stocks. The dividend is payable on February 3, 2025, to holders of record on January 23, 2025.

In other news, CVS share prices rose over expectations that the ongoing wildfire in Los Angeles could lead to an increase in healthcare-related needs, including medical services, healthcare supplies, and pharmaceuticals. According to data, CVS Health has more than 1,000 pharmacies in California.

As of press time, the fire resulted in thousands of people injured, 24 deaths, and $250 billion in economic damages.

6. Nebius Group Inc. (NASDAQ:NBIS)

Nebius Group’s (NBIS) shares rallied by 7.66 percent on Monday to finish at $35.72 apiece after an investment research firm initiated a favorable outlook on the company.

In a report on Monday, BWS Financial gave Nebius Group a favorable outlook with a “buy” rating and a price target of $51 each.

Nebius Group, an artificial intelligence company, has been recognized for its ownership of a data center in Finland along with co-location facilities in Paris and Kansas City. The company also recently gained investor confidence after Nvidia Corp. (NVDA), a leader in AI computing, backed the company.

Analysts said investors cheered Nvidia’s investment in Nebius in hopes that it would propel the latter’s growth similar to SoundHound AI, which in the past year alone, saw its shares surge by more than 600 percent, thanks to the booming AI sector.

5. Mosaic Co. (NYSE:MOS)

Shares of American chemical firm Mosaic (MOS) rose by 8.01 percent on Monday to close at $26.82 each following news that the company entered into an agreement with Fosfatados Centro SPE Ltda for the sale of a phosphate asset owned by Mosaic in Patos de Minas, Brazil.

Upon closing of the transaction, Mosaic is expected to raise $125 million from the sale, payable over six years.

The transaction is subject to regulatory approvals, including approval by the Brazilian Administrative Council for Economic Defense (CADE), and other conditions precedents.

“This transaction aligns with Mosaic’s strategy to scrutinize and monetize non-core assets and redeploy capital to high-returning areas, and we believe the full value of the Patos asset will be realized in the capable hands of Fosfatados Centro,” said Mosaic Executive Vice President Karen Swager. “We are grateful to our employees who have been dedicated to the continued maintenance of the asset.”

4. BridgeBio Pharma Inc. (NASDAQ:BBIO)

BridgeBio Pharma (BBIO) traded 15.99 percent higher on Monday, closing the day at $33.73 as investor sentiment was buoyed by news that its newly approved drug called Attruby has seen a substantial demand with 430 prescriptions from 248 unique healthcare providers.

The early success highlights the medical community’s recognition of the need for new treatment options for patients with this progressive, fatal disease.

In addition, BridgeBio fully enrolled participants in three major market Phase 3 clinical trials. These include FORTIFY for the potential treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9); CALIBRATE for autosomal dominant hypocalcemia type 1 (ADH1); and PROPEL 3 for achondroplasia.

Each trial is expected to complete its last patient visit and release the results in the second half of the year.

3. Option Care Health Inc. (NASDAQ:OPCH)

Shares of Option Care Health (OPCH) rallied by 15.55 percent on Monday to finish the day at $27.72 apiece as investors cheered growth in its preliminary unaudited financial results for the fourth quarter and full year of 2024.

In a statement, Option Care Health (OPCH) said it expects to book a net income of $56.8 to $60.9 million, or diluted earnings per share of $0.33 to $0.36.

Meanwhile, net revenues were projected between $1.34 billion to $1.35 billion, representing approximately 19.2% to 20.1% growth over the fourth quarter of 2023.

While it did not provide any net income outlook for the year, Option Care Health said it expects net revenues this year to grow between $5.2 billion to $5.4 billion year-on-year; adjusted EBITDA of $445 million to $465 million; and adjusted earnings per share of $1.59 to $1.69.

2. Trump Media & Technology Group (NASDAQ:DJT)

Shares of Trump Media (DJT) spiked by 21.52 percent on Monday to finish at $42.91 each, two weeks ahead of incoming president Donald Trump’s return to office.

Monday’s trading marked the company’s largest single-day jump since Trump won the presidential election.

Trump Media, which is owned by the president-elect, is an American media and technology company headquartered in Florida. It runs the Truth Social social media platform.

Trump Media has remained in a precarious financial position over the past couple of years. The company reported yet another quarterly loss in its third-quarter earnings last November. In the three months ended Sept. 30, Trump Media lost $19.2 million, with revenue falling 5.6% to just $1.01 million from a year earlier.

1. Intra-Cellular Therapies Inc. (NASDAQ:ITCI)

Shares of Intra-Cellular (ITCI) jumped by more than 34 percent on Monday to end at $127.19 apiece following news that it was set to be acquired by Johnson & Johnson (JNJ) for $14.6 billion. The transaction would mark the latter’s biggest deal in more than two years, bolstering its presence in the brain disease treatments market.

Johnson & Johnson was said to have offered to buy Intra-Cellular shares at a price of $132 each.

The agreement would provide Johnson & Johnson with access to Intra-Cellular’s oral treatment, Caplyta, which is approved in the U.S. for schizophrenia and bipolar disorder-related depressive episodes, along with other experimental drugs in the pipeline.

While we acknowledge the potential of ITCI, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ITCI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock

Disclosure: None. This article is originally published at Insider Monkey.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.